Edition:
India

Jubilant Life Sciences Ltd (JULS.NS)

JULS.NS on National Stock Exchange of India

728.45INR
3:48pm IST
Change (% chg)

Rs-10.45 (-1.41%)
Prev Close
Rs738.90
Open
Rs737.20
Day's High
Rs744.05
Day's Low
Rs722.00
Volume
114,003
Avg. Vol
555,990
52-wk High
Rs909.00
52-wk Low
Rs234.35

Select another date:

Fri, Jun 19 2020

BRIEF-Jubilant Life Sciences Issues Commercial Papers Of 500 Mln Rupees

* ISSUANCE OF COMMERCIAL PAPERS OF 500 MILLION RUPEES Source text for Eikon: Further company coverage:

BRIEF-India's Jubilant Life Sciences Posts March-Quarter Consol Profit

* MARCH-QUARTER CONSOL NET PROFIT 2.6 BILLION RUPEES VERSUS LOSS OF 992.9 MILLION RUPEES LAST YEAR

India's Jubilant signs licensing deal for Gilead's potential COVID-19 drug

May 12 India's Jubilant Life Sciences Ltd said on Tuesday it had signed a non-exclusive licensing agreement for selling Gilead Sciences Inc's experimental COVID-19 treatment remdesivir in 127 countries, including India. Gilead earlier this month received the U.S. Food and Drug Administration's emergency use authorization for using remdesivir as a treatment against COVID-19, the respiratory illness caused by the novel coronavirus, after the drugmaker provided data showing the drug had

BRIEF-Jubilant Life Sciences Limited Enters Into Licensing Agreement With Gilead For Remdesivir, A Potential Therapy For COVID-19

* JUBILANT LIFE SCIENCES LIMITED ENTERS INTO LICENSING AGREEMENT WITH GILEAD FOR REMDESIVIR, A POTENTIAL THERAPY FOR COVID-19

Select another date: